Auauniversity

Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer (2022) CME Available: https://auau.auanet.org/node/36089 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Differentiate among the subtypes of kidney cancer, with emphasis on clinical management decisions, and outline ways in which knowledge of kidney cancer subtypes can alter surgical approach. 2. Apply advanced strategies for partial nephrectomy for patients with endophytic, hilar and multiple tumors including role of warm ischemia, intraoperative ultrasound, techniques for hemostatic control, the role of off-clamp and selective hilar clamping, the use of the retroperitoneal approach and methods for renorrhaphy. 3. Employ techniques for management of large and/or locally advanced tumors including management of renal vein or inferior vena cava invasion and the use of lymphadenectomy. 4. Identify the role of cytoreductive nephrectomy and/or resection of metastatic foci in patients with adv

Operationalizing Checkpoint Inhibitors in Urologic Practice (2022) CME Available: https://auau.auanet.org/node/36084 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Discuss how to develop a structured approach for administering checkpoint inhibitors in urologic practice as part of a structured program. 2. Manage adverse events from checkpoint inhibitors 3. Identify practice implications of implementing a checkpoint inhibitor program

Financial Toxicity as Drugs Move Earlier into Treatment Paradigm and How This Relates to Disparities in Treatment Patterns CME Available: https://auau.auanet.org/node/35729 Moderator: Jay D. Raman, MD, FACS Co-Hosts: Sarah Psutka, MD, MS LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Define the magnitude of financial toxicity/economic implications across GU malignancies currently. 2. Forecast the potential changes/increases in financial burden associated with moving systemic therapies earlier in treatment paradigms for patients with GU malignancies. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Astellas AstraZeneca Bayer Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc. Pfizer, Inc.

Incorporating Genomic Testing for Prostate Cancer into Your Practice (2022) CME Available: https://auau.auanet.org/node/36074 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Discuss the research studies that led to the approval of genomic testing for prostate cancer 2. Order appropriate genomic testing based on a patient's unique clinical situation 3. State the NCCN and AUA guidelines for genomic testing for prostate cancer 4. Discern the different prognostic clinical endpoints provided by various genomic tests 5. Recognize candidates for, and implications of, germline testing for prostate cancer

Refractory Overactive Bladder: How to Select 3rd-Line Therapies and Optimize Outcomes (2022) CME Available: https://auau.auanet.org/node/36033 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Describe the various 3rd line therapies available to treat refractory overactive bladder (OAB) and be able to discuss the pros and cons of each of the 3rd line therapies available to treat refractory OAB. 2. Explain with the current data regarding outcomes of percutaneous tibial nerve stimulation (PTNS), onabotulinumtoxinA and sacral neuromodulation for treatment of refractory OAB. 3. Outline how to perform PTNS. 4. Report how to perform onabotunlinumtoxinA injections in the office or outpatient setting.. 5. Review techniques in optimal lead placement for sacral neuromodulation, programming and troubleshooting.

Bladder Cancer Treatment Dilemmas: The Cases You Face and What To Do about Them (2022) CME Available: https://auau.auanet.org/node/36049 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Assign risk stratification to patients with bladder cancer. 2. Adapt treatment choices depending on risk of disease and availability of bacillus Calmette-Guérin (BCG). 3. Individualize patient surveillance needs. 4. Provide broadened treatment options beyond intravesical therapy.

Genetic Testing in Prostate Cancer: Clinical Implications for Early Detection and Management of Localized and Advanced Disease Webcast (2022) CME Available: https://auau.auanet.org/node/36044 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening. 2. Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 3. Interpret results of genetic testing and relay this information to patients in order to facilitate shared decision making based on the test results. 4. Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy, and immunotherapy.

CME Available: https://auau.auanet.org/node/35725 Moderator: Jay D. Raman, MD, FACS Co-Hosts: Channa Amarasekera, MD; Simon Rosser, PhD, MPH LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify two specific surgical side effects that may be of interest to a patient who undergoes a prostatectomy (e.g. ED treatment efficacy for anal penetration, climacturia, anejaculation). 2. Ask relevant questions about sexual practices that may impact the side effects that are of interest to them (partner with men, women and both and anal receptive vs. anal penetration sex). ACKNOWLEDGEMENTS Support provided by independent educational grants from: Astellas AstraZeneca Bayer Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc. Pfizer, Inc.

Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment(2022) CME Available: https://auau.auanet.org/node/36065 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Discuss new FDA approved checkpoint inhibitors for treatment and counseling of advanced renal cell carcinoma. 2. Identify indications, risks and benefit of neoadjuvant tyrosine kinase inhibitors for downsizing renal cell carcinoma. 3. Identify appropriate treatment options for management of complex cases.

Contemporary Pharmacotherapy for OAB 2022: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2022) CME Available: https://auau.auanet.org/node/36028 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for OAB. 2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy. 3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies. 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents. 5. Discuss potential future pharmacological pathways and therapies for OAB.

Controversies, Confusion, and the Future of Urologic Post-Operative Opioid Prescribing Reduction Strategies CME Available: https://auau.auanet.org/node/35160 Course Director: Jennifer Robles, MD, MPH Faculty: Chad Brummett, MD; Gregory Auffenberg, MD, MS; Hitya Abraham, MD; Kevan Sternberg, MD After participating in this activity, learners will be able to: 1. Identify at least one non-pharmaceutical method they can practically implement to manage post-operative pain and reduce post-operative opioid prescribing. 2. Discuss multi-modal pain control and identify at least two non-opioid medications which can be used to manage post-operative pain and reduce post-operative opioid prescribing.

Difficult Cases in High-Risk Bladder Cancer: An Evidence-Based Approach (2022) CME Available: https://auau.auanet.org/node/36020 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Identify low, intermediate and high risk non-muscle invasive bladder cancer (NMIBC) 2. Recommend treatment for NMIBC based on risk stratification. 3. Identify bacillus Calmette-Guérin (BCG) unresponsive NMIBC and novel immune-based strategies and intravesical therapies. 4. Manage invasive bladder cancer including surgery, neoadjuvant and adjuvant chemotherapy and bladder preservation strategies in patients with muscle invasive bladder cancer. This will include chemotherapy indications and the role of immunotherapy in the management. 5. Manage upper tract tumors, both low grade and high grade, including renal preservation when appropriate, neoadjuvant therapy when indicated and surgical management strategies.

The Changing Face of Advanced Prostate Cancer 2022(2022) CME Available: https://auau.auanet.org/node/36010 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Identify and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be able to offer additional therapies that extend survival. 2. Recognize high volume new M1 prostate cancer to be able to refer to a genitourinary (GU) medical oncologist for systemic chemotherapy. 3. Diagnose M0 metastatic CRPC and educate patients about using novel oral AR targeted therapeutics added to traditional ADT as a way to improve their patient's overall and radiographic progression-free survival. 4. Identify the differences between these AR targeted oral agents and to educate patients about side effects and toxicities. 5. Describe the latest phase III randomized control trial (RCT) results for new therapies in M1 CRPC.

Host: Jay D. Raman, MD, FACS Guest: Akanksha Mehta, MD, MS For more information or to subscribe to the AUA Update Series, please visit: AUAnet.org/University

Diversity Equity and Inclusion in Urology: What Do We Need to Know? CME Available: https://auau.auanet.org/node/35746 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify the different forms of racism and, more importantly, identify their own subconscious personal bias. 2. Identify the impact of race on medical education, research and clinical care. 3. Identify how DEI initiatives can positively impact the practice of urology. 4. Examine innovative methodologies employed to increase the numbers of underrepresented groups in urology. 5. Participate in activities to encourage and support individualism among urology team members.

Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities CME Available: https://auau.auanet.org/node/36003 LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney and urothelial cancer detection, staging and follow-up. 2. Determine the benefits of combined functional and anatomical information gained through accurate matching of anatomical (CT/MRI) and functional (PET) images. 3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests. 4. Utilize performance characteristics of standard and emerging molecular imaging modalities to stage urologic oncology patients. 5. Describe the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.

CME Available: https://auau.auanet.org/node/35793 Course Director: Amy Krambeck, MD Faculty: Dean Elterman, MD; Steven Kaplan, MD; Lori Lerner, MD ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Cook Medical Olympus Corporation of the Americas LEARNING OBJECTIVES At the conclusion of the activity, participants will be able to: 1. Identify the role of diagnostic testing in making the accurate diagnosis of mLUTS using the new benign BPH guidelines. 2. Recognize the various agents available to treat mLUTS. 3. Describe the indications for the various ablative BPH procedures. 4. Illustrate the impact of current therapeutic strategies on both voiding and sexual dysfunction. 5. Identify the role of the AUA guidelines for BPH for the surgical and medical management of BPH.

CME Available: https://auau.auanet.org/node/35710 Course Director: Stephen A. Boorjian, MD Faculty: Leonard G. Gomella, MD, FACS; David F. Jarrard, MD; Alicia K. Morgans, MD, MPH ACKNOWLEDGMENTS: This educational activity is supported by independent education grants from: Astellas AstraZeneca Merck & Co., Inc. Pfizer, Inc. At the conclusion of the activity, participants will be able to: LEARNING OBJECTIVES: 1. Describe recent developments in the medical management of advanced prostate cancer. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC. 2. Discuss clinical investigations in the treatment of advanced prostate cancer. 3. Analyze the risks and benefits of treatment for advanced prostate cancer. 4. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.

CME Available: https://auau.auanet.org/node/35599 Course Director: David A. Ginsberg, MD Faculty: Anne P. Cameron, MD, FRCSC, FPMRS; Sara M. Lenherr, MD, MS, FPRMS, Eric Rovner, MD; Eric Rovner, MD ACKNOWLEDGEMENTS This educational activity is supported by an independent educational grant from: Urovant LEARNING OBJECTIVES At the conclusion of the activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for OAB and discuss the potential future pharmacological pathways and therapies. 2. Describe the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies. 3. Discuss optimal use of third line therapies in order to maximize clinical benefit. 4. Counsel patients on the pros and cons and risks and benefits of each of the third line therapies for OAB.

Host: Jay D. Raman, MD, FACS Guest: John P. Mulhall, MD Outline: Segment 1: The 4 R's of Scientific Publishing Segment 2: Plagiarism Segment 3: Authorship Issues Segment 4: Conflict of Interest Segment 5: IRB (IACUC)Issues Segment 6: Fabrication/Falsification Segment 7: Reviewer Malpractice Segment 8: Predatory Journals For more information, please visit: AUAnet.org/University